Workflow
赛科希德:上半年净利润4799.99万元,同比下降23.47%

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, primarily due to the impact of medical insurance cost control policies on the demand in the in vitro diagnostic industry [1] Financial Performance - The company achieved an operating revenue of 139 million yuan, representing a year-on-year decrease of 12.62% [1] - The net profit attributable to the parent company was 47.9999 million yuan, down 23.47% year-on-year [1] - The basic earnings per share stood at 0.46 yuan [1] Industry Impact - The decline in revenue is attributed to the effects of medical insurance cost control policies on the demand within the in vitro diagnostic sector [1]